Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 5, 2015	Next Generation Sequencing Veteran Joins Biocept Jason Poole, Ph.D. Brings Years of Next Generation Sequencing Experience to the Biocept Research & Development Team	View HTML Next Generation Sequencing Veteran Joins Biocept 24 KB
Toggle Summary Mar 3, 2015	Biocept to Present at the 27th Annual ROTH Conference SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 27th Annual ROTH Conference 10.5 KB
Toggle Summary Mar 2, 2015	Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor Yale-Affiliated Pathology and Personalized Medicine Leader to Focus on Assays for Immuno-Oncology Therapies	View HTML Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor 24.5 KB
Toggle Summary Feb 25, 2015	Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results SAN DIEGO , Feb. 25, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the	View HTML Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results 19.6 KB
Toggle Summary Feb 23, 2015	Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer SAN DIEGO , Feb. 23, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR™, was	View HTML Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer 25.6 KB
Toggle Summary Feb 9, 2015	Biocept, Inc. Prices $10,000,000 Public Offering SAN DIEGO , Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its	View HTML Biocept, Inc. Prices $10,000,000 Public Offering 22 KB
Toggle Summary Jan 20, 2015	Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer Company launches blood-based 'liquid biopsy' to identify ROS1 rearrangement and better inform NSCLC treatment decisions	View HTML Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer 16.8 KB
Toggle Summary Jan 12, 2015	Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients Blood-Based Liquid Biopsy Technology Launched for Testing Regions of the EGFR Gene Associated With Acquired Resistance in NSCLC Indications	View HTML Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients 23.7 KB
Toggle Summary Jan 8, 2015	Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment Companies to Evaluate Expression and Mutation in NSCLC Therapeutic Target ALK	View HTML Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment 25.5 KB
Toggle Summary Jan 7, 2015	Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network ACPN's Approximately 19 Million Participants Now Have Access to Biocept's Suite of Blood-Based Diagnostics	View HTML Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network 9 KB

Investor Relations

Press Releases

Contact Biocept, Inc.